180 related articles for article (PubMed ID: 34405563)
1. Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report.
Makiguchi T; Tanaka H; Kamata K; Taima K; Kurose A; Tasaka S
Thorac Cancer; 2021 Oct; 12(20):2811-2814. PubMed ID: 34405563
[TBL] [Abstract][Full Text] [Related]
2. Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.
Yorozuya T; Taya T; Yasuda K; Nagano Y; Shioya M; Chiba H; Takahashi H
Thorac Cancer; 2020 Apr; 11(4):1090-1093. PubMed ID: 32045109
[TBL] [Abstract][Full Text] [Related]
3. Acquired amegakaryocytic thrombocytopenia after durvalumab administration.
Suyama T; Hagihara M; Kubota N; Osamura Y; Shinka Y; Miyao N
J Clin Exp Hematop; 2021 Mar; 61(1):53-57. PubMed ID: 33431742
[TBL] [Abstract][Full Text] [Related]
4. [Radiotherapy plus durvalumab for the treatment of locally advanced non-small cell lung cancer-The DOLPHIN trial].
Trommer M
Strahlenther Onkol; 2024 Jul; 200(7):646-648. PubMed ID: 38635049
[No Abstract] [Full Text] [Related]
5. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Kurata T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Faivre-Finn C; Reck M; Vansteenkiste J; Spigel DR; Wadsworth C; Melillo G; Taboada M; Dennis PA; Özgüroğlu M;
N Engl J Med; 2018 Dec; 379(24):2342-2350. PubMed ID: 30280658
[TBL] [Abstract][Full Text] [Related]
6. [Acquired thrombotic thrombocytopenic purpura during durvalumab monotherapy for non-small cell lung cancer].
Shimada S; Kuroiwa K; Narita H; Okamura R; Uesugi Y; Sasaki Y; Watanuki M; Arai N; Kawaguchi Y; Fujiwara S; Yanagisawa K; Hattori N
Rinsho Ketsueki; 2024; 65(1):24-29. PubMed ID: 38311385
[TBL] [Abstract][Full Text] [Related]
7. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone.
Abe T; Saito S; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
Thorac Cancer; 2021 Jan; 12(2):245-250. PubMed ID: 33289347
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report.
Kato Y; Watanabe Y; Yamane Y; Mizutani H; Kurimoto F; Sakai H
Immunotherapy; 2020 Apr; 12(6):373-378. PubMed ID: 32314636
[No Abstract] [Full Text] [Related]
10. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).
Liu J; Bratton E; Yu X; Ladbury C; Wagner J; West H; Massarelli E; Salgia R; Pathak R; Villaflor V; Villalona-Calero M; Amini A
Am J Clin Oncol; 2022 Feb; 45(2):49-54. PubMed ID: 34991107
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer.
Nakamura M; Otsuka T; Hayashi R; Horita T; Ota M; Sakurai N; Takano H; Hayashi T; Kumagai M; Yamada S; Arisawa T
Intern Med; 2020 Nov; 59(21):2711-2717. PubMed ID: 32669493
[TBL] [Abstract][Full Text] [Related]
12. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events.
Miura Y; Mouri A; Kaira K; Yamaguchi O; Shiono A; Hashimoto K; Nishihara F; Shinomiya S; Akagami T; Murayama Y; Abe T; Noda SE; Kato S; Kobayashi K; Kagamu H
Thorac Cancer; 2020 May; 11(5):1280-1287. PubMed ID: 32160383
[TBL] [Abstract][Full Text] [Related]
14. Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab.
Nakashima K; Demura Y; Oi M; Tabata M; Tada T; Shiozaki K; Akai M; Ishizuka T
Intern Med; 2020 Dec; 59(23):3055-3059. PubMed ID: 32727989
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
[TBL] [Abstract][Full Text] [Related]
16. Myositis induced by durvalumab in a patient with non-small cell lung cancer: A case report.
Kobayashi M; Saiki M; Omori C; Ide S; Masuda K; Sogami Y; Hata T; Ishihara H
Thorac Cancer; 2020 Dec; 11(12):3614-3617. PubMed ID: 33103845
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
18. Clinical Course of Preexisting Uveitis during Treatment of Lung Cancer with Durvalumab.
Ahmad TR; Doan T; Gonzales JA; Acharya NR; Tsui E
Ocul Immunol Inflamm; 2020 May; 28(4):566-570. PubMed ID: 31710511
[No Abstract] [Full Text] [Related]
19. Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: A case report.
Domblides M; Geier M; Decroisette C; Descourt R
Thorac Cancer; 2021 Apr; 12(8):1240-1243. PubMed ID: 33624409
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report.
Tao H; Li F; Li R; Han X; Hu Y
Ann Palliat Med; 2020 Sep; 9(5):3623-3628. PubMed ID: 32648466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
